CN1129937A - 作为5ht2c拮抗剂的二氢吲哚衍生物 - Google Patents

作为5ht2c拮抗剂的二氢吲哚衍生物 Download PDF

Info

Publication number
CN1129937A
CN1129937A CN94193185A CN94193185A CN1129937A CN 1129937 A CN1129937 A CN 1129937A CN 94193185 A CN94193185 A CN 94193185A CN 94193185 A CN94193185 A CN 94193185A CN 1129937 A CN1129937 A CN 1129937A
Authority
CN
China
Prior art keywords
indoline
chloro
formyl radical
pyridinylamino formyl
pyridinylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN94193185A
Other languages
English (en)
Chinese (zh)
Inventor
P·汉姆
G·E·琼斯
I·T·福布斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of CN1129937A publication Critical patent/CN1129937A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Eyeglasses (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN94193185A 1993-07-06 1994-06-30 作为5ht2c拮抗剂的二氢吲哚衍生物 Pending CN1129937A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9313913.7 1993-07-06
GB939313913A GB9313913D0 (en) 1993-07-06 1993-07-06 Novel compounds

Publications (1)

Publication Number Publication Date
CN1129937A true CN1129937A (zh) 1996-08-28

Family

ID=10738344

Family Applications (1)

Application Number Title Priority Date Filing Date
CN94193185A Pending CN1129937A (zh) 1993-07-06 1994-06-30 作为5ht2c拮抗剂的二氢吲哚衍生物

Country Status (15)

Country Link
US (1) US5834494A (enExample)
EP (1) EP0707581B1 (enExample)
JP (1) JPH08512299A (enExample)
CN (1) CN1129937A (enExample)
AP (1) AP463A (enExample)
AT (1) ATE149163T1 (enExample)
AU (1) AU7228394A (enExample)
CA (1) CA2166624A1 (enExample)
DE (1) DE69401823T2 (enExample)
GB (1) GB9313913D0 (enExample)
IL (1) IL110204A0 (enExample)
MA (1) MA23254A1 (enExample)
TW (1) TW297023B (enExample)
WO (1) WO1995001976A1 (enExample)
ZA (1) ZA944807B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106278987A (zh) * 2016-08-16 2017-01-04 都创(上海)医药科技有限公司 吲哚啉类化合物的制备方法

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618824A (en) * 1994-03-09 1997-04-08 Merrell Pharmaceuticals Inc. Treatment of obsessive-compulsive disorders with 5-HT2 antagonists
GB9414139D0 (en) * 1994-07-13 1994-08-31 Smithkline Beecham Plc Novel compounds
GB9420521D0 (en) * 1994-10-12 1994-11-30 Smithkline Beecham Plc Novel compounds
WO1996023769A2 (en) * 1995-02-02 1996-08-08 Smithkline Beecham Plc Heterocyclic compounds possessing 5ht2c receptor antagonist activity
NZ301265A (en) * 1995-02-02 1998-12-23 Smithkline Beecham Plc Indole derivatives as 5ht receptor antagonists, preparation and pharmaceutical compositions thereof
GB9517559D0 (en) * 1995-08-26 1995-10-25 Smithkline Beecham Plc Novel compounds
WO1997043281A1 (en) * 1996-05-16 1997-11-20 Allelix Biopharmaceuticals Inc. Thiophene- and furan-tryptamine derivatives
GB9612885D0 (en) * 1996-06-20 1996-08-21 Smithkline Beecham Plc Novel compounds
GB9612883D0 (en) * 1996-06-20 1996-08-21 Smithkline Beecham Plc Novel compounds
US6362009B1 (en) 1997-11-21 2002-03-26 Merck & Co., Inc. Solid phase synthesis of heterocycles
FR2778662B1 (fr) * 1998-05-12 2000-06-16 Adir Nouveaux composes cycliques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CA2347095A1 (en) * 1998-10-16 2000-04-27 Takeda Chemical Industries, Ltd. Nitrogen-containing condensed heterocyclic derivatives, their production and agent
US6453357B1 (en) 1999-01-07 2002-09-17 Cisco Technology, Inc. Method and system for processing fragments and their out-of-order delivery during address translation
US6465467B1 (en) 1999-05-21 2002-10-15 Biovitrum Ab Certain aryl-aliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases
CA2374898C (en) * 1999-05-21 2009-12-08 Biovitrum Ab Pyrazinyl-piperazine compounds, their use and preparation
UA77650C2 (en) 1999-12-06 2007-01-15 Lundbeck & Co As H Use of serotonin reuptake inhibitor in combination with deramcyclane
FR2810979B1 (fr) * 2000-06-29 2002-08-23 Adir Nouveaux derives de diphenyluree, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GB0019950D0 (en) * 2000-08-12 2000-09-27 Smithkline Beecham Plc Compounds
SE0004245D0 (sv) 2000-11-20 2000-11-20 Pharmacia Ab Novel compounds and their use
ATE241155T1 (de) * 2001-07-09 2003-06-15 Cit Alcatel Verbinder für optische fasern
US6861440B2 (en) 2001-10-26 2005-03-01 Hoffmann-La Roche Inc. DPP IV inhibitors
FR2837823B1 (fr) * 2002-03-27 2005-04-08 Servier Lab Nouveaux derives d'indoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
BR0311970A (pt) 2002-06-19 2005-03-29 Biovitrum Ab Novos compostos, seu uso e preparação
ATE437876T1 (de) 2003-06-20 2009-08-15 Hoffmann La Roche Hexahydropyridoisochinoline als dpp-iv- inhibitoren
MXPA05013904A (es) 2003-06-20 2006-02-24 Hoffmann La Roche Derivados de pirido[2,1-a] isoquinolinas como inhibidores de dipeptidil-peptidasa iv(dpp-iv).
EP1931622B1 (en) * 2005-09-13 2011-08-24 Bayer CropScience AG Phenyloxy substituted phenylamidine derivatives as pesticides
US9052304B2 (en) 2009-03-13 2015-06-09 Terrasep, Llc Methods and apparatus for centrifugal liquid chromatography

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4428881A (en) * 1977-12-23 1984-01-31 Gulf Oil Corporation Control of unwanted vegetation with N-carbamylindolines
JPH06500551A (ja) * 1990-09-13 1994-01-20 ビーチャム・グループ・パブリック・リミテッド・カンパニー ５ｈｔ受容体アンタゴニストとしてのインドールウレア
CA2142721A1 (en) * 1992-08-20 1994-03-03 Ian T. Forbes Condensed indole derivatives as 5ht and 5ht antagonists

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106278987A (zh) * 2016-08-16 2017-01-04 都创(上海)医药科技有限公司 吲哚啉类化合物的制备方法

Also Published As

Publication number Publication date
WO1995001976A1 (en) 1995-01-19
EP0707581A1 (en) 1996-04-24
DE69401823D1 (de) 1997-04-03
MA23254A1 (fr) 1995-04-01
IL110204A0 (en) 1995-01-24
AP463A (en) 1996-02-19
ATE149163T1 (de) 1997-03-15
EP0707581B1 (en) 1997-02-26
ZA944807B (en) 1996-01-04
US5834494A (en) 1998-11-10
TW297023B (enExample) 1997-02-01
DE69401823T2 (de) 1997-08-28
CA2166624A1 (en) 1995-01-19
GB9313913D0 (en) 1993-08-18
AP9400653A0 (en) 1994-07-31
JPH08512299A (ja) 1996-12-24
AU7228394A (en) 1995-02-06

Similar Documents

Publication Publication Date Title
CN1028105C (zh) 四氢吡啶衍生物的制备方法
CN1221533C (zh) 7－氨基－1h－吲哚衍生物
CN1158258C (zh) 肾上腺素能α1B受体拮抗药
CN1098263C (zh) 吡啶－2－基－甲胺衍生物、其制备方法及其作为药物的用途
CN1257891C (zh) 含氮五员环化合物
CN1024547C (zh) 一类环胺化合物的制备方法
CN1193025C (zh) 新的1,3－二氢－2h－吲哚－2－酮衍生物,它们的制备方法以及含有它们的药物组合物
CN1079464A (zh) 治疗包括胆碱能功能降低的病症有价值的吲哚酮和吲哚二酮的衍生物的制备方法
CN1085556A (zh) 抗偏头痛的吲哚-3-基烷基哌嗪的4-嘧啶基和吡啶基衍生物
CN1049654C (zh) 哌嗪衍生物及含其的药物组合物和用途
CN1053904C (zh) 新型n－吡啶基甲酰胺和衍生物,其制备方法及其药物组合物
CN1210521A (zh) 异喹啉衍生物及医药
CN1402712A (zh) 新的杂环化合物及其盐和它们的医药用途
CN1121717A (zh) 杂环化合物及其制备方法和用途
CN1585749A (zh) 类大麻苷受体配体
CN1060841A (zh) 喹唑啉衍生物及其制备方法
CN1239952A (zh) 用作nos抑制剂的6－苯基吡啶基－2－胺衍生物
CN1531527A (zh) 咔唑衍生物及其作为神经肽y5受体配体的用途
CN1829711A (zh) 用于治疗炎性和过敏性病症的新杂环化合物、其制备方法和含有它们的药物组合物
CN1072219C (zh) 二氮杂䓬酮、其生产和用途
CN1268133A (zh) 含有稠合环取代基的作为nos抑制剂的2－氨基吡啶
CN1035178C (zh) 芳酰胺衍生物
CN1250542C (zh) 具有抗肿瘤活性的2－(1h－吲哚－3－基)－2－氧代－乙酰胺
CN1045583A (zh) 四氢苯并咪唑衍生物
CN1039228C (zh) 叔胺化合物、其盐，及含该类化合物或其盐的药物组合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C01 Deemed withdrawal of patent application (patent law 1993)
WD01 Invention patent application deemed withdrawn after publication